HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced that the U.S. Food and Drug Administration (FDA) has accepted its HeartBeam System into the Total Product Life Cycle Advisory Program (TAP) Pilot. This acceptance follows the receipt of Breakthrough Device Designation earlier this month. The TAP program provides dedicated FDA advisors, expedited regulatory feedback, and access to healthcare providers, patient advocacy groups, and insurers to help accelerate development and patient access.
The acceptance applies to HeartBeam's 3D electrocardiogram (ECG) technology, which is being developed to assess potential heart attacks outside traditional medical settings. The company estimates the heart attack assessment market opportunity at approximately $15 billion within a broader cardiac platform opportunity exceeding $40 billion. This news is significant because it could lead to faster regulatory review and ultimately quicker patient access to a novel technology that aims to detect heart attacks in non-hospital settings, potentially saving lives and reducing healthcare costs.
HeartBeam expects to seek FDA alignment on its multicenter pivotal study design in the coming months, with patient enrollment anticipated to begin in the first quarter of 2027. The study is intended to support a future regulatory submission expanding the HeartBeam System's indications to include heart attack assessment. The company is also evaluating eligibility for the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to accelerate Medicare access to eligible Breakthrough devices. The HeartBeam System is not currently cleared for heart attack detection, and TAP participation does not guarantee future FDA authorization or insurance coverage.
For investors, the TAP acceptance represents a potential acceleration in the path to market for HeartBeam's heart attack assessment technology. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company's newsroom at https://nnw.fm/BEAT. For more details on the company's cleared indications, refer to the Cleared Indications for Use.
To view the full press release, visit https://nnw.fm/NdfEK. This announcement was originally distributed by NetworkNewsWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. NetworkNewsWire provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution among other services. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
